Internal Medicine, Endocrinology, Diabetes, & Metabolism · Bristol, CT
NPI
1457889024
Since 2017
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
15 Riverside Avenue
Bristol, CT, 06010
Phone (860) 940-6300
Groups this clinician bills Medicare through
Medicare paid, 2024
$15K
234 services
Medicare patients, 2024
80
Average age 71
Drug cost, 2024
$2.0M
3,523 prescriptions
Company payments, 2025
$1,890
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Khary Edwards was code 99214 (office e&m - established), 140 times for 63 patients. In total Khary Edwards billed 234 services in 7 codes, and Medicare paid $15K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-08-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 140 | 63 | $73.47 | $10K |
| 95251 Test - Miscellaneous | Facility | 58 | 26 | $26.53 | $1,539 |
| 99204 Office E&M - New | Facility | 20 | 20 | $102.68 | $2,054 |
By year: 2022 $13K for 223 services; 2023 $24K for 552 services; 2024 $15K for 234 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 86 | 29 | $3.21 | $276 |
Medicare prescription drug claims, 2024
In 2024, the drug Khary Edwards prescribed most often to Medicare patients was Ozempic (Semaglutide), with 411 prescriptions and refills. In total Khary Edwards wrote 3,523 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 411 | 472 | 68 | $449K |
| Mounjaro Tirzepatide | 323 | 345 | 56 | $368K |
| Levothyroxine Sodium Generic | 157 | 349 | 35 | $1,335 |
| Glimepiride Generic | 149 | 319 | 47 | $814 |
| Metformin Hcl Er Metformin Hcl | 135 | 317 | 47 | $1,324 |
| Jardiance Empagliflozin | 135 | 252 | 40 | $143K |
| Pioglitazone Hcl Generic | 134 | 286 | 32 | $1,046 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 118 | 298 | 42 | $21K |
| Humalog Kwikpen U-100 Insulin Lispro | 112 | 217 | 43 | $36K |
| Atorvastatin Calcium Generic | 108 | 297 | 37 | $864 |
| Tresiba Flextouch U-100 Insulin Degludec | 95 | 199 | 28 | $74K |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 89 | 166 | 19 | $107K |
| Metformin Hcl Generic | 83 | 173 | 22 | $406 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 83 | 232 | 39 | $11K |
| Rosuvastatin Calcium Generic | 71 | 149 | 20 | $725 |
Brand drugs: 2,020 claims; generic drugs: 1,246 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Khary Edwards $1,890 ($1,890 in general payments such as food, travel and fees) from 30 companies. The largest payer was Amgen Inc. with $237.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 11 | $237 |
| Novo Nordisk Inc NVO | 10 | $225 |
| Lilly USA, LLC LLY | 8 | $196 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $136 |
| Abbott Laboratories ABT | 6 | $127 |
| Ascendis Pharma Endocrinology Inc ASND | 4 | $104 |
| UCB, Inc. UCB.BR | 3 | $67.26 |
| ANI Pharmaceuticals, Inc. ANIP | 2 | $56.15 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $54.15 |
| Madrigal Pharmaceuticals MDGL | 2 | $53.31 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.